A new trading day began on Monday, with Standard BioTools Inc (NASDAQ: LAB) stock price down -5.06% from the previous day of trading, before settling in for the closing price of $1.58. LAB’s price has ranged from $1.21 to $3.04 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -0.06%. Meanwhile, its annual earnings per share averaged 62.06%. With a float of $360.19 million, this company’s outstanding shares have now reached $372.26 million.
Let’s determine the extent of company efficiency that accounts for 539 employees. In terms of profitability, gross margin is 48.57%, operating margin of -81.68%, and the pretax margin is -79.83%.
Standard BioTools Inc (LAB) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 3.24%, while institutional ownership is 75.15%. The most recent insider transaction that took place on Nov 12 ’24, was worth 123,098. Before that another transaction happened on Sep 09 ’24, when Company’s Former Officer proposed sale 45,851 for $2.00, making the entire transaction worth $91,725.
Standard BioTools Inc (LAB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 62.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.06% during the next five years compared to 8.72% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Here are Standard BioTools Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.71, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Looking closely at Standard BioTools Inc (NASDAQ: LAB), its last 5-days average volume was 2.42 million, which is a drop from its year-to-date volume of 2.46 million. As of the previous 9 days, the stock’s Stochastic %D was 2.77%. Additionally, its Average True Range was 0.14.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 24.17%, which indicates a significant increase from 2.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.61% in the past 14 days, which was lower than the 102.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9084, while its 200-day Moving Average is $2.2052. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.5600. Second resistance stands at $1.6200. The third major resistance level sits at $1.6600. If the price goes on to break the first support level at $1.4600, it is likely to go to the next support level at $1.4200. Should the price break the second support level, the third support level stands at $1.3600.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
With a market capitalization of 518.97 million, the company has a total of 372,259K Shares Outstanding. Currently, annual sales are 106,340 K while annual income is -74,660 K. The company’s previous quarter sales were 44,970 K while its latest quarter income was -26,940 K.
